Investors to Lead Class Action Against PROCEPT BioRobotics Corp Over Significant Losses

Investors Seek to Hold PROCEPT BioRobotics Accountable

On August 12, 2026, Levi & Korsinsky, LLP announced a call to investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) who have faced financial losses to join a class action lawsuit against the company. The substantial decline in share prices, which reportedly dropped by over 75%, raises crucial questions regarding corporate accountability and investor protection.

The Significant Drop in Share Prices

Just a few years ago, PROCEPT’s shares peaked around $100 per share but have since tumbled to under $25. This staggering decline occurred amidst increasing concerns about the company's commercial practices and transparency. Investors who acquired shares of PRCT between February 28, 2024, and February 25, 2026, may be eligible to participate in this lawsuit, providing they can document their losses.

Allegations Against Former COO Hisham Shiblaq

The lawsuit notably cites Hisham Shiblaq, the former Chief Commercial Officer of PROCEPT, alleging his central role in misleading investor communications. Shiblaq is accused of misrepresenting the company's actual performance regarding handpiece sales tied to the AquaBeam Robotic Systems. The lawsuit points out that while sales figures appeared robust, they were reportedly inflated due to undisclosed discounting practices and inventory mismanagement.

Critics question whether investors received all necessary information concerning the company’s inventory levels and actual procedure volume, leading many to believe they were intentionally misled. The discrepancy between reported sales and actual procedure data paints a concerning picture about how PROCEPT handled its financial disclosures.

Legal Framework and Implications

This case is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 alongside SEC Rule 10b-5, which governs the securities industry and aims to protect investors from fraudulent practices. Plaintiffs allege that senior executives, such as Shiblaq, had considerable control over public statements that impacted PRCT’s market performance and, by extension, its investors.